[HTML][HTML] T-cell responses to immunodominant listeria epitopes limit vaccine-directed responses to the colorectal cancer antigen, guanylyl cyclase C
The Gram-positive bacterium Listeria monocytogenes (Lm) is an emerging platform for
cancer immunotherapy. To date, over 30 clinical trials have been initiated testing Lm cancer …
cancer immunotherapy. To date, over 30 clinical trials have been initiated testing Lm cancer …
T-Cell Responses to Immunodominant Listeria Epitopes Limit Vaccine-Directed Responses to the Colorectal Cancer Antigen, Guanylyl Cyclase C
JC Flickinger, J Singh, Y Yarman, RD Carlson, J Barton… - 2022 - jdc.jefferson.edu
Abstract The Gram-positive bacterium Listeria monocytogenes (Lm) is an emerging platform
for cancer immunotherapy. To date, over 30 clinical trials have been initiated testing Lm …
for cancer immunotherapy. To date, over 30 clinical trials have been initiated testing Lm …
[HTML][HTML] T-Cell Responses to Immunodominant Listeria Epitopes Limit Vaccine-Directed Responses to the Colorectal Cancer Antigen, Guanylyl Cyclase C
JC Flickinger Jr, J Singh, Y Yarman… - Frontiers in …, 2022 - ncbi.nlm.nih.gov
Abstract The Gram-positive bacterium Listeria monocytogenes (Lm) is an emerging platform
for cancer immunotherapy. To date, over 30 clinical trials have been initiated testing Lm …
for cancer immunotherapy. To date, over 30 clinical trials have been initiated testing Lm …
T-Cell Responses to Immunodominant Listeria Epitopes Limit Vaccine-Directed Responses to the Colorectal Cancer Antigen, Guanylyl Cyclase C
JC Flickinger Jr, J Singh, Y Yarman… - Frontiers in …, 2022 - pubmed.ncbi.nlm.nih.gov
The Gram-positive bacterium Listeria monocytogenes (Lm) is an emerging platform for
cancer immunotherapy. To date, over 30 clinical trials have been initiated testing Lm cancer …
cancer immunotherapy. To date, over 30 clinical trials have been initiated testing Lm cancer …
T-Cell Responses to Immunodominant Listeria Epitopes Limit Vaccine-Directed Responses to the Colorectal Cancer Antigen, Guanylyl Cyclase C.
JC Flickinger Jr, J Singh, Y Yarman… - Frontiers in …, 2022 - europepmc.org
Abstract The Gram-positive bacterium Listeria monocytogenes (Lm) is an emerging platform
for cancer immunotherapy. To date, over 30 clinical trials have been initiated testing Lm …
for cancer immunotherapy. To date, over 30 clinical trials have been initiated testing Lm …
[引用][C] T-Cell Responses to Immunodominant Listeria Epitopes Limit Vaccine-Directed Responses to the Colorectal Cancer Antigen, Guanylyl Cyclase C
JC Flickinger Jr, J Singh, Y Yarman… - … in Immunology (Web), 2022 - jglobal.jst.go.jp
T-Cell Responses to Immunodominant Listeria Epitopes Limit Vaccine-Directed Responses
to the Colorectal Cancer Antigen, Guanylyl Cyclase C | Article Information | J-GLOBAL Art J-GLOBAL …
to the Colorectal Cancer Antigen, Guanylyl Cyclase C | Article Information | J-GLOBAL Art J-GLOBAL …
T-Cell Responses to Immunodominant Listeria Epitopes Limit Vaccine-Directed Responses to the Colorectal Cancer Antigen, Guanylyl Cyclase C.
JC Flickinger Jr, J Singh, Y Yarman… - Frontiers in …, 2022 - europepmc.org
Abstract The Gram-positive bacterium Listeria monocytogenes (Lm) is an emerging platform
for cancer immunotherapy. To date, over 30 clinical trials have been initiated testing Lm …
for cancer immunotherapy. To date, over 30 clinical trials have been initiated testing Lm …